Chlamydia Infection Diagnostics Market By Diagnostic Technique (Nucleic Acid Amplification Tests (NAATs), Direct Fluorescent Antibody (DFA) Tests, Enzyme-Linked Immunosorbent Assays (ELISA), Rapid Point-of-Care (POC) Tests, Other Molecular Assays), By Sample Type (Urine Samples, Vaginal Swabs, Cervical Swabs, Urethral Swabs, Rectal/Pharyngeal Samples), By End User (Hospitals and Clinics, Diagnostic Laboratories, Sexual Health & STD Clinics, Home Care & Telehealth Platforms, Academic and Research Institutions), By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Chlamydia Infection Diagnostics Market: Expanding Molecular Screening, Multiplex NAAT Adoption, and the Shift Toward Self-Collected, Decentralized, and At-Home STI Testing Ecosystems

The Global Chlamydia Infection Diagnostics Market was valued at USD 1.32 billion in 2025 and is projected to reach USD 2.13 billion by 2032, expanding at a CAGR of 7.1% during 2026–2032.

 

Chlamydia infection diagnostics is primarily a molecular-testing market built around the detection of Chlamydia trachomatis nucleic acid from urogenital and extragenital specimens. Nucleic acid amplification tests (NAATs) have become the core clinical technology because they combine high analytical performance with urine, vaginal, cervical, rectal, and pharyngeal collection workflows. WHO describes NAATs as the most commonly used and gold-standard diagnostic approach, while CDC guidance identifies first-catch urine as an optimal urogenital specimen for men and vaginal swabs as the preferred specimen for women.

 

Demand is increasingly shaped by screening rather than symptomatic diagnosis alone. Large numbers of infections are asymptomatic, making routine screening, repeat testing, self-collection, testing at multiple anatomical sites, and easier access outside traditional laboratories commercially important. The market is consequently expanding beyond central-laboratory CT testing toward multiplex sexual-health panels, self-collected specimens, rapid point-of-care PCR systems, mail-in home collection and, more recently, fully at-home molecular testing.

 

Why Do NAATs Hold the Largest Revenue Share in the Chlamydia Infection Diagnostics Market?

Within the supplied market segmentation, NAATs account for approximately 60%–61.2% of chlamydia diagnostic revenue, giving molecular testing a wide lead over culture, antigen detection and other diagnostic approaches. The commercial advantage is broader than test accuracy. NAAT platforms can process urine and multiple swab types, automate large laboratory volumes and combine chlamydia with gonorrhea and other sexually transmitted infections in the same testing workflow.

The underlying testing population remains substantial. WHO's current chlamydia fact sheet cites an estimated 128.5 million new infections among adults aged 15–49 worldwide in 2020, with estimated prevalence of 4.0% among women and 2.5% among men in that age group. WHO also notes that urine can be less sensitive than genital and extragenital swab specimens and supports self-collection as an option where appropriate.

This favors suppliers that can turn existing molecular installations into broader sexual-health testing platforms. Hologic's Aptima Combo 2 assay, for example, runs on the Panther platform and supports several specimen types, including self- and clinician-collected vaginal swabs. Hologic also positions its broader Aptima sexual and vaginal health menu so multiple infections and disease states can be tested through the same automated platform. BD, meanwhile, offers CT/GC and CT/GC/TV assays for the BD MAX system, allowing laboratories to detect multiple common non-viral STIs from a single testing workflow.

Multiplexing matters commercially because instrument utilization no longer depends on chlamydia volume alone. Laboratories can spread automation, maintenance, extraction and workflow costs across CT, gonorrhea, trichomoniasis and other assays. That creates a competitive advantage for suppliers with broad menus and installed analyzer bases rather than companies selling a standalone chlamydia assay.

 

How Is Specimen Choice Shifting Demand Toward Vaginal Self-Collection and Site-Specific Testing?

Urine testing remains commercially important because first-catch urine provides a simple, non-invasive specimen and is particularly well suited to male urogenital screening. CDC identifies first-catch urine as an optimal NAAT specimen for men. For women, however, vaginal swabs have become the preferred urogenital specimen, which affects demand for collection kits, transport media and assays validated for self-collected vaginal specimens.

The performance difference is commercially meaningful. A 2023 meta-analysis comparing paired specimens from women reported pooled chlamydia sensitivity of 94.1% for vaginal swabs versus 86.9% for urine. The difference supports health-system efforts to improve collection practices rather than simply increasing total test ordering. Self-collection also removes the need for a pelvic examination solely to obtain the specimen, allowing collection in primary-care facilities, sexual-health clinics, pharmacies, remote programs and home-testing models.

Extragenital testing creates another growth layer. A U.S. national laboratory analysis covering 45 million chlamydia tests performed from 2019 through 2023 found that 71.6% were performed for women. Among women, 98.1% of samples were urogenital, while only 1.5% were pharyngeal and 0.4% rectal. Yet chlamydia positivity was 4.3% in urogenital, 2.0% in pharyngeal and 7.3% in rectal specimens.

That disparity is strategically important. Urine or vaginal testing cannot identify an infection confined to a rectal or pharyngeal site, so diagnostic completeness depends on exposure-based anatomical sampling. Commercial laboratories and molecular-test manufacturers therefore gain incremental demand when clinical practice expands from single-site urogenital testing to appropriately selected multi-site testing.

Cepheid's Xpert CT/NG, for example, supports automated real-time PCR detection across urogenital as well as pharyngeal and rectal sites, positioning the assay for settings where broader anatomical coverage is required. BD similarly markets extragenital CT/GC testing on its BD COR platform, showing how broad specimen claims have become a competitive differentiator within major molecular portfolios.

 

How Do Screening Gaps Create Additional Revenue Opportunities Beyond Rising Case Counts?

Chlamydia diagnostics should not be modeled simply as reported infections multiplied by tests per case. A large share of testing occurs before diagnosis because screening recommendations target asymptomatic populations. The USPSTF recommends chlamydia screening for sexually active women aged 24 years or younger and for women aged 25 years or older who are at increased risk.

Actual screening performance remains below complete coverage. Medicaid's Core Set Data Dashboard reports a 2024 median chlamydia screening rate of 47.1% among sexually active women aged 16–20 and 56.0% among women aged 21–24. From a market perspective, this gap represents unperformed diagnostic volume within an already recognized screening population. Improvements in primary-care ordering, digital outreach, self-collection and quality-measure performance can expand testing even when infection incidence is stable or declining.

The latest U.S. surveillance data also show why reported case growth should not be treated as the sole market indicator. CDC's provisional 2024 surveillance reported an 8% decline in chlamydia cases from 2023, marking the second consecutive annual decrease. A decline in reported infections can coexist with commercial opportunities in better screening coverage, repeat testing, broader anatomical sampling and decentralized diagnostics because reported case numbers are affected by who is tested and where testing occurs.

The U.S. laboratory dataset reinforces the importance of younger populations. Among people aged 15–24, urogenital chlamydia positivity reached 8.7% in women and 12.2% in men in the 2019–2023 national laboratory analysis. High positivity concentrated within younger age groups keeps adolescent and young-adult screening programs important to reference laboratories, molecular assay suppliers, primary-care networks and digital sexual-health providers.

 

How Are At-Home and Near-Patient Molecular Tests Changing Chlamydia Diagnostic Channels?

The most commercially disruptive development is the movement of molecular diagnostics closer to the patient. Earlier home-testing models generally involved self-collection followed by shipment to a centralized laboratory. In 2023, FDA authorized the LetsGetChecked Simple 2 Test, the first diagnostic test for chlamydia and gonorrhea with over-the-counter at-home sample collection; specimens are then sent to a laboratory for testing.

In March 2025, FDA authorized the Visby Medical Women's Sexual Health Test, the first over-the-counter test for chlamydia, gonorrhea and trichomoniasis that can be performed completely at home. The single-use molecular device uses a self-collected vaginal swab and provides results in approximately 30 minutes. FDA reported that it identified 97.2% of positive and 98.8% of negative chlamydia samples in its supporting data.

The distinction between these models matters commercially. Mail-to-laboratory services compete mainly on convenience, privacy and digital access while retaining centralized laboratory economics. Fully at-home molecular platforms move both specimen collection and testing away from the laboratory, creating a separate revenue opportunity in disposable molecular devices, digital result delivery and consumer distribution.

Near-patient systems create a third channel. Roche's cobas liat CT/NG uses real-time PCR and provides results in approximately 20 minutes from male urine or vaginal swabs, positioning molecular STI testing in settings where a same-visit answer has operational value. These systems do not replace high-throughput central laboratories economically for every specimen, but they can capture testing where turnaround time and patient retention are more important than maximum batch efficiency.

International screening data show that remote channels can already account for substantial testing volume. In England, 547,308 chlamydia tests were conducted among young women in 2025, and internet services supplied 38.8% of those tests, or 212,162 tests. Internet self-sampling volumes nevertheless fell 13.3% from 2024, demonstrating that digital availability alone does not guarantee continuous volume growth.

 

What Defines the Evolving Architecture of Chlamydia Diagnostics Across Testing Methods, Specimen Pathways, and Care Delivery Settings?

Market Breakdown by Diagnostic Technique

Nucleic Acid Amplification Tests (NAATs) accounted for an estimated 61.0% market share, equivalent to approximately USD 0.81 billion in 2025, and are projected to grow at an estimated CAGR of 7.2%. NAATs retain the largest segment because laboratories rely on their high analytical performance, compatibility with urine and multiple swab specimens, automated workflows and ability to combine chlamydia with other STI targets on multiplex molecular platforms.

Direct Fluorescent Antibody (DFA) Tests represented an estimated 6.0% market share, or approximately USD 0.08 billion in 2025, with an estimated CAGR of 3.8%. The segment continues to serve selected laboratory requirements but is expanding more slowly as molecular methods replace labor-intensive diagnostic approaches in routine chlamydia screening.

Enzyme-Linked Immunosorbent Assays (ELISA) held an estimated 10.0% market share, valued at approximately USD 0.13 billion in 2025, and are expected to expand at an estimated CAGR of 5.0%. ELISA remains relevant in selected testing environments where established immunoassay infrastructure and cost considerations influence procurement, although increasing molecular-test adoption limits its relative growth.

Rapid Point-of-Care (POC) Tests accounted for an estimated 15.0% market share, equivalent to approximately USD 0.20 billion in 2025, and are projected to record an estimated CAGR of 8.6%. The segment is benefiting from demand for faster specimen-to-result workflows that can reduce dependence on centralized laboratories and improve testing access in clinics, community settings and decentralized sexual-health programs.

Other Molecular Assays represented an estimated 8.0% market share, or approximately USD 0.11 billion in 2025, and are expected to grow at an estimated CAGR of 7.8%. Demand is increasing as laboratories and decentralized testing providers adopt broader molecular formats that support multiplex STI detection, simplified workflows and alternative testing settings.

 

Sample Type Segmentation of the Chlamydia Infection Diagnostics Market

Urine Samples held an estimated 36.0% market share, equivalent to approximately USD 0.48 billion in 2025, and are projected to grow at an estimated CAGR of 7.3%. Urine remains the largest sample segment because first-catch collection is non-invasive and widely used for male urogenital screening, supporting high testing volumes across clinics and diagnostic laboratories.

Vaginal Swabs accounted for an estimated 31.0% market share, valued at approximately USD 0.41 billion in 2025, and are expected to expand at an estimated CAGR of 7.8%. Growth is supported by higher diagnostic sensitivity in women and increasing acceptance of self-collected vaginal specimens across clinical, remote and home-based testing workflows.

Cervical Swabs represented an estimated 17.0% market share, or approximately USD 0.22 billion in 2025, with an estimated CAGR of 5.8%. Cervical sampling remains established in clinician-led testing environments, although simpler vaginal self-collection and molecular urine workflows are reducing its relative growth rate.

Urethral Swabs held an estimated 7.0% market share, equivalent to approximately USD 0.09 billion in 2025, and are projected to grow at an estimated CAGR of 5.5%. Their role is becoming more selective because non-invasive first-catch urine testing provides a more convenient alternative for many male urogenital diagnostic workflows.

Others, including Rectal and Pharyngeal Samples, accounted for an estimated 9.0% market share, valued at approximately USD 0.12 billion in 2025, and are expected to expand at an estimated CAGR of 8.2%. This segment is growing faster as exposure-based testing identifies infections that urogenital specimens cannot detect and as molecular platforms receive broader extragenital specimen claims.

 

End User Segmentation of the Chlamydia Infection Diagnostics Market

Hospitals and Clinics accounted for an estimated 34.0% market share, equivalent to approximately USD 0.45 billion in 2025, and are projected to grow at an estimated CAGR of 6.5%. These settings retain the largest end-user share because routine consultations, preventive screening, pregnancy-related testing and symptomatic STI evaluation continue to generate substantial recurring diagnostic demand.

Diagnostic Laboratories held an estimated 30.0% market share, valued at approximately USD 0.40 billion in 2025, and are expected to expand at an estimated CAGR of 7.1%. Large laboratories benefit from centralized NAAT processing, automation, high specimen throughput and multiplex testing, supporting recurring reagent and platform utilization.

Sexual Health & STD Clinics represented an estimated 17.0% market share, or approximately USD 0.22 billion in 2025, with an estimated CAGR of 6.7%. Their demand is sustained by targeted screening, higher-risk populations, repeat testing and increased use of site-specific urogenital and extragenital specimens.

Home Care & Telehealth Platforms accounted for an estimated 12.0% market share, equivalent to approximately USD 0.16 billion in 2025, and are projected to record the fastest estimated CAGR of 9.6%. Growth is supported by mail-in self-collection, digital ordering, privacy-focused sexual-health services and the emergence of fully at-home molecular STI testing.

Academic and Research Institutions held an estimated 7.0% market share, valued at approximately USD 0.09 billion in 2025, and are expected to grow at an estimated CAGR of 5.4%. Demand is associated with epidemiological surveillance, assay evaluation, diagnostic-method research and STI-focused public-health studies rather than routine high-volume clinical testing.

 

How Does Chlamydia Diagnostic Demand Differ Across North America, Europe and Asia-Pacific?

North America holds an estimated 38.0% market share, valued at approximately USD 0.50 billion in 2025, and is projected to grow at an estimated CAGR of 6.4%, remaining commercially attractive because screening recommendations, payer quality measures, large reference-laboratory networks, and an active molecular-testing industry create substantial recurring test volume. The recent decline in reported U.S. chlamydia cases is a volume headwind if accompanied by lower testing, but Medicaid screening rates show that considerable guideline-defined testing remains unrealized. FDA authorization of both mail-in self-collection and fully at-home molecular testing also makes the United States an important market for testing-channel innovation.

Europe combines a large reported infection burden with substantial differences in national testing intensity and is estimated to account for a 29.0% market share, valued at approximately USD 0.38 billion in 2025, and is projected to grow at an estimated CAGR of 7.2%. ECDC reported 213,443 confirmed chlamydia cases from 27 EU/EEA countries in 2024, with a crude notification rate of 63.4 per 100,000 population among countries with comprehensive surveillance. ECDC cautions that differences in testing policies, case-finding strategies and reporting materially affect comparisons between countries. For diagnostic companies, country-level testing infrastructure and screening policy can consequently matter more than headline notification rates when prioritizing commercial markets.

Asia-Pacific presents a different opportunity profile because screening coverage and diagnostic infrastructure vary considerably between countries. The region accounts for an estimated 24.0% market share, valued at approximately USD 0.32 billion in 2025, and is projected to grow at an estimated CAGR of 8.0%. Australia provides one of the region's stronger surveillance signals: the Kirby Institute reported 101,742 chlamydia diagnoses in 2024, with approximately half occurring among people aged 20–29. In markets with established molecular laboratories, opportunities center on automation, multiplexing and self-collection; in less-developed testing networks, accessibility and affordable specimen-to-result workflows remain more important constraints.

Latin America, the Middle East, and Africa together account for about 9% of the global Chlamydia Infection Diagnostics Market, valued at roughly USD 0.12 billion in 2025, and are expected to grow at a CAGR of around 6.6%. Growth is supported by improving access to NAAT-based molecular testing, rising STI awareness, and expanding public-health screening programs, although adoption remains uneven due to limited laboratory infrastructure and lower routine screening rates compared to developed regions. Latin America is seeing gradual uptake of NAAT testing in urban labs, the Middle East is benefiting from government-led STI awareness and hospital screening initiatives, and Africa is slowly expanding testing through donor-funded sexual health and infectious disease programs, all contributing to steady but moderate regional growth.

 

How Are Leading Companies Competing Through Broader Chlamydia Testing Ecosystems?

The competitive landscape includes large molecular-diagnostics companies with installed laboratory platforms alongside newer entrants targeting decentralized and consumer testing.

Hologic

Hologic's Aptima Combo 2 is positioned around CT/NG molecular testing on the automated Panther platform. Its broader Aptima sexual and vaginal health portfolio can use common collection approaches across multiple conditions, allowing laboratories to consolidate testing on one automation platform. This gives Hologic an advantage where high throughput, broad assay menus and recurrent reagent consumption determine purchasing decisions.

Roche

Roche addresses both centralized and decentralized molecular testing. Its cobas liat CT/NG provides approximately 20-minute PCR testing close to the patient, while the broader cobas molecular portfolio gives Roche access to higher-volume laboratory workflows. The ability to compete across different testing settings reduces dependence on a single care channel.

Becton, Dickinson and Company

BD's BD MAX CT/GC and CT/GC/TV assays focus on automated multiplex molecular testing, while the company's broader STI portfolio extends into other laboratory platforms and extragenital testing. Its commercial proposition centers on consolidating multiple STI targets and diagnostic workflows rather than relying on CT-only test volume.

Cepheid

Cepheid's Xpert CT/NG combines cartridge-based automated PCR with urogenital and extragenital specimen coverage. Its fit within the GeneXpert platform gives the company a route into laboratories and decentralized settings that value simplified workflows and faster results without constructing a separate high-throughput molecular laboratory.

Visby Medical

Visby Medical represents the emerging fully decentralized segment. FDA authorization of its Women's Sexual Health Test in 2025 moved molecular CT/NG/TV testing into a completely at-home format, giving the company a differentiated position from conventional laboratory systems and mail-in collection providers.

LetsGetChecked

LetsGetChecked competes through a digital home-collection model. Its FDA-authorized Simple 2 Test allows consumers to collect specimens at home and return them to a laboratory, positioning the company between conventional clinic testing and fully self-contained home molecular diagnostics.

 

Analyst Perspective: What Will Determine Commercial Growth in the Chlamydia Infection Diagnostics Market Through 2032?

The main growth drivers through 2030 are expected to be higher screening uptake, wider use of self-collected vaginal swabs, expanded extragenital testing, and growing adoption of multiplex CT/NG/TV molecular assays, along with rapid and at-home testing options.

High-throughput NAAT systems will continue to dominate routine laboratory testing, while decentralized PCR platforms and home-based tests will help reach patients who may not access traditional clinics. Companies with broad test menus, multiple specimen approvals, and easy collection formats are better positioned to grow than those focused only on chlamydia testing.

However, overall testing demand can fluctuate even as access improves. For example, U.S. chlamydia cases declined by 8% in 2024, and testing volumes among young women in England also fell in 2025. As a result, future market growth toward the projected USD 2.24 billion by 2030 will depend more on closing screening gaps and expanding testing access than on rising infection rates alone. 

 

Chlamydia Infection Diagnostics Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.32 Billion
Revenue Forecast in 2032	USD 2.13 Billion
Overall Growth Rate	CAGR of 7.1% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Diagnostic Technique, By Sample Type, By End User, By Geography
By Diagnostic Technique	Nucleic Acid Amplification Tests (NAATs), Direct Fluorescent Antibody (DFA) Tests, Enzyme-Linked Immunosorbent Assays (ELISA), Rapid Point-of-Care (POC) Tests, Other Molecular Assays
By Sample Type	Urine Samples, Vaginal Swabs, Cervical Swabs, Urethral Swabs, Rectal/Pharyngeal Samples
By End User	Hospitals and Clinics, Diagnostic Laboratories, Sexual Health & STD Clinics, Home Care & Telehealth Platforms, Academic and Research Institutions
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising STI screening programs, increasing adoption of NAAT-based molecular diagnostics, growing demand for self-collected specimens, expansion of multiplex STI testing panels, increasing adoption of decentralized and at-home molecular testing
Customization Option	Available upon request